Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$337.60 USD

337.60
8,150,947

-4.06 (-1.19%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $338.00 +0.40 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies

by Zacks Equity Research

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Zacks Equity Research

Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline

by Zacks Equity Research

AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the closing of the recent trading day, Amgen (AMGN) stood at $320.71, denoting a -2.12% move from the preceding trading day.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus

by Abhinab Dasgupta

LTM, GM and AMGN highlight Zacks' recent stock-picking wins, delivering notable gains across airlines, autos and biotech despite choppy markets.

Zacks Equity Research

Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar?

by Zacks Equity Research

Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Ekta Bagri headshot

BMY vs AMGN: Which Biotech Stock Is More Resilient Now?

by Ekta Bagri

AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.

Zacks Equity Research

Can Amgen's MariTide Take on Leaders in the Obesity Space?

by Zacks Equity Research

AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.

Zacks Equity Research

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.